Export 23 results:
Author Title [ Type(Asc)] Year
Filters: Author is Edwards, Kathryn M  [Clear All Filters]
Journal Article
T. R. Talbot, Stapleton, J. T., Brady, R. C., Winokur, P. L., Bernstein, D. I., Germanson, T., Yoder, S. M., Rock, M. T., Crowe, J. E., and Edwards, K. M., Vaccination success rate and reaction profile with diluted and undiluted smallpox vaccine: a randomized controlled trial., JAMA, vol. 292, no. 10, pp. 1205-12, 2004.
L. Patricia Stadler, Bernstein, D. I., S Callahan, T., Ferreira, J., Simone, G. A. Gorgone, Edwards, K. M., Stanberry, L. R., and Rosenthal, S. L., Seroprevalence of cytomegalovirus (CMV) and risk factors for infection in adolescent males., Clin Infect Dis, vol. 51, no. 10, pp. e76-81, 2010.
L. Patricia Stadler, Bernstein, D. I., S Callahan, T., Turley, C. B., Munoz, F. M., Ferreira, J., Acharya, M., Simone, G. A. Gorgone, Patel, S. M., Edwards, K. M., and Rosenthal, S. L., Seroprevalence and Risk Factors for Cytomegalovirus Infections in Adolescent Females., J Pediatric Infect Dis Soc, vol. 2, no. 1, pp. 7-14, 2013.
F. M. Munoz, Patel, S. M., Jackson, L. A., Swamy, G. K., Edwards, K. M., Frey, S. E., Petrie, C. R., Sendra, E. A., and Keitel, W. A., Safety and immunogenicity of three seasonal inactivated influenza vaccines among pregnant women and antibody persistence in their infants., Vaccine, vol. 38, no. 33, pp. 5355-5363, 2020.
R. Libster, McNeal, M., Walter, E. B., Shane, A. L., Winokur, P., Cress, G., Berry, A. A., Kotloff, K. L., Sarpong, K., Turley, C. B., Harrison, C. J., Pahud, B. A., Marbin, J., Dunn, J., El-Khorazaty, J., Barrett, J., and Edwards, K. M., Safety and Immunogenicity of Sequential Rotavirus Vaccine Schedules., Pediatrics, vol. 137, no. 2, p. e20152603, 2016.
F. M. Munoz, Jackson, L. A., Swamy, G. K., Edwards, K. M., Frey, S. E., Stephens, I., Ault, K., Winokur, P., Petrie, C. R., Wolff, M., Patel, S. M., and Keitel, W. A., Safety and immunogenicity of seasonal trivalent inactivated influenza vaccines in pregnant women., Vaccine, vol. 36, no. 52, pp. 8054-8061, 2018.
N. B. Halasa, Gerber, M. A., Berry, A. A., Anderson, E. L., Winokur, P., Keyserling, H., Eckard, A. Ross, Hill, H., Wolff, M. C., McNeal, M. M., Edwards, K. M., and Bernstein, D. I., Safety and Immunogenicity of Full-Dose Trivalent Inactivated Influenza Vaccine (TIV) Compared With Half-Dose TIV Administered to Children 6 Through 35 Months of Age., J Pediatric Infect Dis Soc, vol. 4, no. 3, pp. 214-24, 2015.
B. C Creech, Dekker, C. L., Ho, D., Phillips, S., Mackey, S., Murray-Krezan, C., Pau, M. Grazia, Hendriks, J., Brown, V., Dally, L. G., Versteege, I., and Edwards, K. M., Randomized, placebo-controlled trial to assess the safety and immunogenicity of an adenovirus type 35-based circumsporozoite malaria vaccine in healthy adults., Hum Vaccin Immunother, vol. 9, no. 12, pp. 2548-57, 2013.
A. C. Galassie, Goll, J. B., Samir, P., Jensen, T. L., Hoek, K. L., Howard, L. M., Allos, T. M., Niu, X., Gordy, L. E., C Creech, B., Hill, H., Joyce, S., Edwards, K. M., and Link, A. J., Proteomics show antigen presentation processes in human immune cells after AS03-H5N1 vaccination., Proteomics, vol. 17, no. 12, 2017.
W. H. Chen, Winokur, P. L., Edwards, K. M., Jackson, L. A., Wald, A., Walter, E. B., Noah, D. L., Wolff, M., and Kotloff, K. L., Phase 2 assessment of the safety and immunogenicity of two inactivated pandemic monovalent H1N1 vaccines in adults as a component of the U.S. pandemic preparedness plan in 2009., Vaccine, vol. 30, no. 28, pp. 4240-8, 2012.
T. S Callahan, Wolff, M., Hill, H. R., and Edwards, K. M., Impact of body mass index on immunogenicity of pandemic H1N1 vaccine in children and adults., J Infect Dis, vol. 210, no. 8, pp. 1270-4, 2014.
R. B. Belshe, Frey, S. E., Graham, I. L., Anderson, E. L., Jackson, L. A., Spearman, P., Edupuganti, S., Mulligan, M. J., Rouphael, N., Winokur, P., Dolor, R. J., Woods, C. W., Walter, E. B., Chen, W. H., Turley, C., Edwards, K. M., C Creech, B., Hill, H., and Bellamy, A. R., Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial., JAMA, vol. 312, no. 14, pp. 1420-8, 2014.
L. A. Jackson, Patel, S. M., Swamy, G. K., Frey, S. E., C Creech, B., Munoz, F. M., Artal, R., Keitel, W. A., Noah, D. L., Petrie, C. Rodeheffer, Wolff, M., and Edwards, K. M., Immunogenicity of an inactivated monovalent 2009 H1N1 influenza vaccine in pregnant women., J Infect Dis, vol. 204, no. 6, pp. 854-63, 2011.
P. Winokur, Sahly, H. M. El, Mulligan, M. J., Frey, S. E., Rupp, R., Anderson, E. J., Edwards, K. M., Bernstein, D. I., Schmader, K., Jackson, L. A., Chen, W. H., Hill, H., and Bellamy, A., Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65 years and older., Vaccine, vol. S0264-410X, no. 20, pp. 31504-31508, 2021.
D. I. Bernstein, Edwards, K. M., Dekker, C. L., Belshe, R., Talbot, H. K. B., Graham, I. L., Noah, D. L., He, F., and Hill, H., Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults., J Infect Dis, vol. 197, no. 5, pp. 667-75, 2008.
L. A. Jackson, Campbell, J. D., Frey, S. E., Edwards, K. M., Keitel, W. A., Kotloff, K. L., Berry, A. A., Graham, I., Atmar, R. L., C Creech, B., Thomsen, I. P., Patel, S. M., Gutierrez, A. F., Anderson, E. L., Sahly, H. M. El, Hill, H., Noah, D. L., and Bellamy, A. R., Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial., JAMA, vol. 314, no. 3, pp. 237-46, 2015.
R. W. Frenck, Belshe, R., Brady, R. C., Winokur, P. L., Campbell, J. D., Treanor, J., Hay, C. M., Dekker, C. L., Walter, E. B., Cate, T. R., Edwards, K. M., Hill, H., Wolff, M., Leduc, T., and Tornieporth, N., Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults., Vaccine, vol. 29, no. 34, pp. 5666-74, 2011.
K. L. Kotloff, Halasa, N. B., Harrison, C. J., Englund, J. A., Walter, E. B., King, J. C., C Creech, B., Healy, S. A., Dolor, R. J., Stephens, I., Edwards, K. M., Noah, D. L., Hill, H., and Wolff, M., Clinical and immune responses to inactivated influenza A(H1N1)pdm09 vaccine in children., Pediatr Infect Dis J, vol. 33, no. 8, pp. 865-71, 2014.
L. M. Howard, Hoek, K. L., Goll, J. B., Samir, P., Galassie, A., Allos, T. M., Niu, X., Gordy, L. E., C Creech, B., Prasad, N., Jensen, T. L., Hill, H., Levy, S. E., Joyce, S., Link, A. J., and Edwards, K. M., Cell-Based Systems Biology Analysis of Human AS03-Adjuvanted H5N1 Avian Influenza Vaccine Responses: A Phase I Randomized Controlled Trial., PLoS One, vol. 12, no. 1, p. e0167488, 2017.
I. N. Mbawuike, Atmar, R. L., Patel, S. M., Corry, D. B., Winokur, P. L., Brady, R. C., Chen, W. H., Edwards, K. M., C Creech, B., Walter, E. B., Frey, S. E., Belshe, R. B., Goll, J. B., Hill, H., and Keitel, W. A., Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccine., Vaccine, vol. 34, no. 4, pp. 547-554, 2016.
L. E. Widdice, Hoagland, R., S Callahan, T., Kahn, J. A., Harrison, C. J., Pahud, B. A., Frey, S. E., Berry, A. A., Kotloff, K. L., Edwards, K. M., Mulligan, M. J., Sudman, J., Nakamura, A., and Bernstein, D. I., Caregiver and adolescent factors associated with delayed completion of the three-dose human papillomavirus vaccination series., Vaccine, vol. 36, no. 11, pp. 1491-1499, 2018.
L. M. Howard, Goll, J. B., Jensen, T. L., Hoek, K. L., Prasad, N., Gelber, C. E., Levy, S. E., Joyce, S., Link, A. J., C Creech, B., and Edwards, K. M., AS03-Adjuvanted H5N1 Avian Influenza Vaccine Modulates Early Innate Immune Signatures in Human Peripheral Blood Mononuclear Cells., J Infect Dis, vol. 219, no. 11, pp. 1786-1798, 2019.
L. E. Widdice, Unger, E. R., Panicker, G., Hoagland, R., S Callahan, T., Jackson, L. A., Berry, A. A., Kotloff, K., Frey, S. E., Harrison, C. J., Pahud, B. A., Edwards, K. M., Mulligan, M. J., Sudman, J., and Bernstein, D. I., Antibody responses among adolescent females receiving two or three quadrivalent human papillomavirus vaccine doses at standard and prolonged intervals., Vaccine, vol. 36, no. 6, pp. 881-889, 2018.